Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension
2018-001187-33Phase 3Active
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing ralinepag plus background therapy with placebo plus background therapy (2 arms). Primary endpoint: Time to first adjudicated protocol-defined clinical failure event. Started Oct 2018; status: active.
02
Drugs
ralinepag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2018-001187-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001187-33.